Abstract. The threat of a dirty bomb or other major radiological contamination presents a danger of large-scale radiation exposure of the population. Because major components of such contamination are likely to be actinides, actinide decorporation treatments that will reduce radiation exposure must be a priority. Current therapies for the treatment of radionuclide contamination are limited and extensive efforts must be dedicated to the development of therapeutic, orally bioavailable, actinide chelators for emergency medical use. 
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Abstract. The threat of a dirty bomb or other major radiological contamination presents a danger of large-scale radiation exposure of the population. Because major components of such contamination are likely to be actinides, actinide decorporation treatments that will reduce radiation exposure must be a priority. Current therapies for the treatment of radionuclide contamination are limited and extensive efforts must be dedicated to the development of therapeutic, orally bioavailable, actinide chelators for emergency medical use. Using a biomimetic approach based on the similar biochemical properties of plutonium(IV) and iron(III), siderophore-inspired multidentate hydroxypyridonate ligands have been designed and are unrivaled in terms of actinide-affinity, selectivity and efficiency. A perspective on the preclinical development of two hydroxypyridonate actinide decorporation agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), is presented. The chemical syntheses of both candidate compounds have been optimized for scale-up. Baseline preparation and analytical methods suitable for manufacturing large amounts have been established. Both ligands show much higher actinideremoval efficacy than the currently approved agent, diethylenetriaminepentaacetic acid (DTPA),
with different selectivity for the tested isotopes of plutonium, americium, uranium and neptunium. No toxicity is observed in cells derived from three different human tissue sources treated in vitro up to ligand concentrations of 1 mM, and both ligands were well tolerated in rats when orally administered daily at high doses (> 100 µmol kg -1 day -1 ) over 28 days under good laboratory practice (GLP) guidelines. Both compounds are on an accelerated development pathway towards clinical use.
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INTRODUCTION
The only practical therapy to reduce the substantial health consequences of internal actinide contamination is treatment with chelating agents that form excretable actinide complexes (Durbin 2006 , Durbin 2008 (Durbin 2008) . Because of the growing threat of a nuclear terrorist event involving the release of radionuclides such as actinides, the development of improved decorporation therapies and better delivery systems for chelators has become a research priority in the area of radiological and nuclear threat countermeasures (Pellmar and Rockwell 2005, Cassatt et al. 2008) . The project described here specifically addresses the urgent need to develop and implement an improved therapy for radioisotope contamination of a large population.
In the past 3 decades, much research has resulted from a collaborative program between the Lawrence Berkeley National Laboratory and the University of California at Berkeley to use the similar coordination features of Fe 3+ and Pu 4+ (including charge-to-ionic-radius ratios of 4.6 and 4.3, respectively) and develop synthetic analogs of the microbial iron transporters siderophores as potential therapeutic actinide chelators (Gorden et al. 2003 , Durbin 2008 (Gorden et al. 2003 , Durbin 2008 . Both ligands incorporate hydroxypyridinone actinide-binding units that are linked to a polyamine scaffold through amide linkages. They are considerably more effective than DTPA at removing actinides and are orally active (Gorden et al. 2003 , Durbin 2008 .
[Figure 1]
The two candidate ligands have been advanced through the initial phases of the preclinical development pathway by successfully scaling up the synthesis from the research scale to the 100 g level and establishing baseline preparation and analytical methods suitable for manufacturing larger amounts under good manufacturing practice (GMP) guidelines. The ligand materials prepared in the 100 g lots were used for carrying out systematic efficacy studies for the two chelators in a mouse model, establishing preclinical safety of the candidate ligands under good laboratory practice (GLP) guidelines in rats, and completing in vitro cellular-level toxicity studies in human cell lines. Results from these studies are presented here and confirm that both 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO) are not only efficacious, but also non-toxic at the doses selected and warrant further development for emergency use in the case of a radiological incident.
METHODS
Ligand Synthesis and Analysis. The 100 g scale synthesis of both ligands was performed at Albany Molecular Research, Inc., Albany, NY. Because the synthetic processes followed published procedures with slight modifications, and standard characterization of the final products (NMR, MS, IR, UV-Vis) conformed to published data (Scarrow et al. 1985 , White et al. 1988 , Xu et al. 1995 , Xu et al. 1995 , Burgada et al. 2001 , purity analyses only are reported here. µmol kg -1 oral for 5-LIO(Me-3,2-HOPO)) was contained in 0.5 mL of 0.14 M NaCl, the pH being adjusted to 7.4-8.4 with 1 N NaOH. Under isoflurane anesthesia, groups of five female Swiss-Webster mice (85 d, 34 ± 2 g) were injected in a lateral tail vein with 0.2 mL of an actinide solution containing the following radioactivities and metal masses: 238 Pu (0.7 kBq, 0.001 µg) or 241 Am (0.9 kBq, 0.007 µg) in 0.008 M sodium citrate and 0.14 M NaCl, pH 4; 233 UO 2 Cl 2 (0.6 kBq, 1.7 µg), or 237 NpO 2 Cl 2 (0.1 kBq, 4.1 µg) in 0.14 M NaCl, pH 4. Ligands were administered at 1 h after the actinide by ip injection to normally fed mice or orally (gastric 6 intubation) to mice that had been fasted for 16 h. Each 5-mouse group was housed together in a plastic stock cage lined with a 0.5 cm layer of highly absorbent low-ash pelleted cellulose bedding (Alpha-dry) for separation of urine and feces. All mice were given water and food ab libitum (for fasted mice, food became available at 4 h after the actinide injection), and were sacrificed at 24 h after the actinide injection. Details of sample collection, preparation, radioactivity measurements, and data reduction have been published previously (Durbin et al. 1994 , Xu et al. 1995 , Durbin et al. 1998 , Durbin et al. 2000 . were floating), rinsed, spun to remove trypsin, and resuspended in 500 µl phenol red free media.
GLP
Aliquots of 100 µl were used for each MTT test (Sigma, performed in triplicates for statistical significance); the colorimetric reading was conducted in 96 well plates and a plate reader was used to record the absorption at 570 and 630 nm. Aliquots of 50 µl were used for the Trypan Blue viability assay and 150 µl-aliquots were fixed with glutaraldehyde for the Alcian Blue viability test. The results of these two dye-exclusion viability tests were analyzed as a function of drug treatment concentration and time, and replicate studies were evaluated for statistical significance.
SYNTHESIS SCALE-UP AND ANALYTICAL METHODS
The methodologies for the synthetic preparations were scaled from the 1 to 2 g laboratory level to the 100 g level for both ligands, establishing the baseline for new preparation and analytical methods under Non-Clinical Safety Studies protocols (NCSS) suitable for extension to GMP manufacturing of larger amounts. The large-scale preparation of 3,4,3-LI(1,2-HOPO) followed previously described methods that were implemented without significant optimization (Scarrow et al. 1985 , White et al. 1988 , Burgada et al. 2001 , the six synthetic steps were performed with a 35% overall yield (Scheme 1), starting from 6-bromopicolinic acid. The synthesis of 5-LIO(Me-3,2-HOPO) required slight modifications in the previously described procedures to limit the number of high-pressure reactions and chromatographic purification steps (Xu et al. 1995 , Xu et al. 1995 , the seven steps were achieved with a 27% overall yield (Scheme 2), starting from 3-hydroxy-2(1H)-pyridinone. The purity of the resulting products was estimated by high pressure liquid chromatography (HPLC) to be 93% and 99% for 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), respectively. Several parameters were optimized in the development of reliable HPLC analytical methods for each compound, including the mobile phase solvent, the flow rate, the injection volume and concentration, as well as a pre-analysis pacification step to free the system of any metal contamination. Both methods were verified under GLP guidelines and were used to determine the chromatographic purity, concentration, homogeneity, and stability of test article dose formulations in subsequent studies. (Durbin 2008) . Extended investigations of the efficacy of the compounds, when produced on a large scale, including dosage effectiveness, delayed administration, and repeated administration, will be reported elsewhere.
[Schemes 1-2]

IN VIVO ACTINIDE REMOVAL EFFICACY
[ Table 1 for 28 days of daily oral administration, although some alterations in clinical chemistry parameters were observed at dose levels of 30 and 10 µmol kg -1 day -1 . Because a statistically significant (p < 0.05) 18% increase in serum phosphorous was observed in the low dose females when compared to the control animals, the No Observed Adverse Effect Level (NOAEL) for 3,4,3-LI(1,2-HOPO) is less than 10 µmol kg -1 day -1 when administered for 28 days by oral gavage to female rats, and less than 30 µmol kg -1 day -1 when administered to male rats. The
Maximum Tolerated Dose (MTD) for 3,4,3-LI(1,2-HOPO) is estimated to be higher than 100
µmol kg -1 day -1 for 28 days of oral administration to rats.
In the case of 5-LIO(Me-3,2-HOPO), the serum sodium level was elevated (2 to 4% increase, as compared to the control animals) in the mid-and high-dose groups at both sacrifice time points for males and in all three dose groups at the Day 42 sacrifice time point for females.
Elevated, but reversible, levels of serum calcium were observed in male rats sacrificed 1 day after the last administered dose in the mid-(8% increase) and high-(6% increase) dose groups.
The liver to body weight ratio was decreased relative to controls in high-dose females 1 day and 2 weeks after the last administered dose (14% and 11% decrease, respectively) and in mid-dose females 2 weeks after the last administered dose (10% decrease). These findings are of unknown toxicological significance and it is unclear whether the differences in female liver to body weight ratios are meaningful since no other liver parameters in these groups were statistically different from controls [e.g. serum chemistry (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, albumin, total bilirubin, and total protein levels), absolute liver weight, and histopathology]. Overall, 5-LIO(Me-3,2-HOPO) was well tolerated in male and female rats at the high dose of 150 µmol kg -1 day -1 for 28 days of daily oral administration. Because of the elevated serum sodium levels, the NOAEL for 5-LIO(Me-3,2-HOPO) is less than 30 µmol kg -1 day -1 when administered for 28 days by oral gavage to female rats, and less than 100 µmol kg -1 day -1 when administered to male rats. The MTD is estimated to be higher than 150 µmol kg -1 day -1 for 28 consecutive days of oral administration to rats.
CELLULAR-LEVEL TOXICITY STUDIES
In vitro ligand toxicities for ligands tested separately were screened in cultured normal human cells from specific organs, kidney and lung, that could potentially be at risk as target assay was used to evaluate the cellular metabolic activity of these primary human cells (Mossman 1983 , Holman et al. 2002 . Dye exclusion techniques were also used to score for cell viability (Yip and Auersperg 1972, Holman et al. 2002) . Initial decrements of metabolic activities were noted in both kidney cell types and lung cells at concentrations higher than 1 mM of 3,4,3-LI(1,2-HOPO) or 5-LIO(Me-3,2-HOPO), with little to no toxicity below 1 mM for either ligand (Figure 2 ). Vital staining confirmed these findings. Cell morphology of treated and fixed cells showed changes in cytoskeletal actin filament organization at concentrations higher than 10 mM of 3,4,3-LI(1,2-HOPO) or 5-LIO(Me-3,2-HOPO), but no distinct changes in cell and nuclei shape were observed with either ligand at concentrations below 1 mM.
[ Figure 2] 
SUMMARY
In the development program of the two selected actinide decorporation agents, 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO), considerable progress has been made in scaling up the synthesis of both agents from the research scale to the 100 g level and in establishing baseline preparation and analytical methods suitable for further manufacturing. The produced material was used in Phase I in vivo efficacy assays, which confirmed that both candidate compounds promote the decorporation of a series of actinides, including 238 Pu(IV), 241 Am(III), 233 U(VI)O 2 , and 237 Np(V)O 2 , and are significantly more efficacious than DTPA, the current therapy standard.
In addition, preclinical GLP safety studies were performed in rats, to provide data of suitable quality and integrity to support applications to the Food and Drug Administration and other regulatory agencies. Overall, both 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO) were well tolerated in male and female rats at the high dose of 100 µmol kg -1 day -1 and 150 µmol kg -1 day -1 , respectively, for 28 days of daily oral administration. The corresponding MTDs were estimated to be higher than the doses used in those studies. Finally, the cellular toxicity breakpoint for both agents was estimated at 1 mM in cultured normal human cells from specific organs that are potentially at risk, which corresponds to ligand concentrations 100 fold higher than concentrations used for high-dose experiments. These evaluations are critical for the development of 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO) for clinical purposes; further research efforts will be directed toward the accelerated advancement of these unrivaled actinide decorporation agents for therapeutic use. c Excreta of each five-mouse group were pooled and SD is not available.
d Mean is significantly less than for appropriate actinide-injected controls (t-test, p ≤ 0.01) (Mack 1967 ).
e Mean is significantly less than for mice similarly treated with CaNa 3 -DTPA.
